|Ms. Helen Molloy||Financial Controller||224.24k||N/A||N/A|
|Prof. Marilyn A. Anderson A.O., AO, B.Sc., BSc (Hons), FAA, FAICD, FT||Chief Science Officer||48.63k||N/A||1951|
|Dr. Nancy Sacco||Chief Development Officer||175.25k||N/A||N/A|
|Mr. Geoffrey Paul Kempler B.Sc.||MD & Chairman||N/A||N/A||1955|
|Dr. Neil Forrester||Vice President of Business Development||N/A||N/A||N/A|
|Ms. Leanne Ralph||Company Secretary||N/A||N/A||N/A|
Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics in Australia. The company's lead drug candidate is the pezadeftide, which has completed phase II clinical trials for the treatment of onychomycosis. Hexima Limited was incorporated in 1997 and is headquartered in Bundoora, Australia.
Hexima Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.